DAFNA Capital Management
Latest statistics and disclosures from DAFNA Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, XBI, CMPS, STXS, NKTR, and represent 40.18% of DAFNA Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ASND (+$13M), DNLI (+$11M), NKTR (+$11M), PODD (+$7.8M), EWTX, KYMR, ANL, SNDX, NGEN, KIDS.
- Started 17 new stock positions in NVCT, CRBP, DSGN, Scynexis, ENGN, ANL, NGEN, KYMR, QTTB, Kardigan Ord. TNYA, Seaport Therapeutics, ARTV, RNA, ASND, EDIT, EPRX.
- Reduced shares in these 10 stocks: DAWN (-$21M), XBI (-$19M), BHVN (-$11M), MBX (-$9.0M), Ascendis Pharma A/s (-$5.9M), CMPS (-$5.8M), Kalvista Pharmaceuticals (-$5.4M), Ascendis Pharma A S (-$5.3M), BCAX, CYTK.
- Sold out of its positions in Ascendis Pharma A S, Ascendis Pharma A/s, DAWN, Engene Holdings, FULC, Kalvista Pharmaceuticals, KPTI, NMRA, ORIC, SCYX. ZBIO, NAMS.
- DAFNA Capital Management was a net seller of stock by $-39M.
- DAFNA Capital Management has $524M in assets under management (AUM), dropping by 19.28%.
- Central Index Key (CIK): 0001389933
Tip: Access up to 7 years of quarterly data
Positions held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 88 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 20.1 | $105M | -3% | 563k | 187.28 |
|
| Spdr S&p Biotech Etf Etf (XBI) | 5.9 | $31M | -38% | 197k | 158.25 |
|
| Compass Pathways Sponsored Ads (CMPS) | 5.4 | $29M | -16% | 2.0M | 14.15 |
|
| Stereotaxis Com New (STXS) | 4.5 | $24M | 14M | 1.72 |
|
|
| Nektar Therapeutics Com New (NKTR) | 4.2 | $22M | +92% | 318k | 69.81 |
|
| Denali Therapeutics (DNLI) | 3.6 | $19M | +132% | 739k | 25.72 |
|
| Ideaya Biosciences (IDYA) | 3.5 | $19M | +4% | 497k | 37.27 |
|
| AtriCure (ATRC) | 3.2 | $17M | 597k | 27.98 |
|
|
| Xenon Pharmaceuticals (XENE) | 2.9 | $15M | 251k | 60.36 |
|
|
| Cytokinetics Com New (CYTK) | 2.8 | $15M | -20% | 172k | 85.19 |
|
| Arcus Biosciences Incorporated (RCUS) | 2.6 | $14M | 442k | 30.83 |
|
|
| Ascendis Pharma A/s Ord Shs (ASND) | 2.5 | $13M | NEW | 49k | 266.72 |
|
| Neurocrine Biosciences (NBIX) | 1.9 | $9.7M | -18% | 58k | 168.53 |
|
| Axogen (AXGN) | 1.8 | $9.7M | -16% | 209k | 46.19 |
|
| Insulet Corporation (PODD) | 1.8 | $9.4M | +469% | 62k | 152.25 |
|
| Edgewise Therapeutics (EWTX) | 1.8 | $9.2M | +102% | 227k | 40.63 |
|
| Bicara Therapeutics (BCAX) | 1.6 | $8.5M | -32% | 285k | 29.69 |
|
| Ishares Nasdaq Biotech Indx Etf (IBB) | 1.5 | $8.1M | -31% | 43k | 190.19 |
|
| Syndax Pharmaceuticals (SNDX) | 1.4 | $7.3M | +54% | 335k | 21.86 |
|
| Maplight Therapeutics (MPLT) | 1.2 | $6.1M | 171k | 35.84 |
|
|
| Larimar Therapeutics (LRMR) | 1.2 | $6.1M | 2.0M | 3.05 |
|
|
| Century Therapeutics (IPSC) | 1.1 | $5.9M | 2.4M | 2.45 |
|
|
| Dex (DXCM) | 1.1 | $5.8M | 86k | 67.35 |
|
|
| Immunovant (IMVT) | 1.1 | $5.8M | 150k | 38.53 |
|
|
| Inogen (INGN) | 1.0 | $5.5M | 845k | 6.45 |
|
|
| Tandem Diabetes Care (TNDM) | 1.0 | $5.4M | 355k | 15.09 |
|
|
| Alkermes SHS (ALKS) | 1.0 | $5.3M | -27% | 101k | 52.40 |
|
| Stoke Therapeutics (STOK) | 0.8 | $4.3M | 131k | 32.72 |
|
|
| Allogene Therapeutics (ALLO) | 0.8 | $4.2M | +45% | 2.0M | 2.08 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.8 | $4.0M | -6% | 400k | 10.00 |
|
| Lakefront Biotherapeutics Nv Spon Adr | 0.7 | $3.9M | 130k | 29.98 |
|
|
| Orthopediatrics Corp. (KIDS) | 0.7 | $3.6M | +97% | 189k | 19.13 |
|
| Cybin Com New (HELP) | 0.6 | $3.4M | +3% | 514k | 6.61 |
|
| Rapport Therapeutics (RAPP) | 0.6 | $3.1M | 75k | 41.67 |
|
|
| Kymera Therapeutics (KYMR) | 0.6 | $3.1M | NEW | 27k | 114.67 |
|
| Proqr Therapeutics Nv Shs Euro (PRQR) | 0.5 | $2.8M | -2% | 1.5M | 1.86 |
|
| Neurogene (NGNE) | 0.5 | $2.8M | +57% | 89k | 31.45 |
|
| Adlai Nortye Sponsored Ads (ANL) | 0.5 | $2.8M | NEW | 240k | 11.50 |
|
| Procept Biorobotics Corp (PRCT) | 0.5 | $2.7M | 120k | 22.58 |
|
|
| Aquestive Therapeutics (AQST) | 0.5 | $2.7M | +75% | 646k | 4.16 |
|
| Celldex Therapeutics Com New (CLDX) | 0.5 | $2.5M | 69k | 37.21 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.5 | $2.5M | 47k | 53.67 |
|
|
| Align Technology (ALGN) | 0.5 | $2.4M | -6% | 14k | 168.66 |
|
| Viking Therapeutics (VKTX) | 0.4 | $2.3M | 60k | 39.01 |
|
|
| Nervgen Pharma Ord (NGEN) | 0.4 | $2.2M | NEW | 1.1M | 2.06 |
|
| Biohaven (BHVN) | 0.4 | $2.0M | -83% | 138k | 14.88 |
|
| Maze Therapeatics (MAZE) | 0.4 | $1.9M | +85% | 65k | 29.84 |
|
| Alector (ALEC) | 0.3 | $1.8M | 908k | 2.01 |
|
|
| Lexeo Therapeutics (LXEO) | 0.3 | $1.8M | 377k | 4.66 |
|
|
| Profound Medical Corp Com New (PROF) | 0.3 | $1.7M | 260k | 6.65 |
|
|
| Atrium Therapeutics (RNA) | 0.3 | $1.7M | NEW | 128k | 13.45 |
|
| Annexon (ANNX) | 0.3 | $1.7M | +152% | 298k | 5.71 |
|
| Cytomx Therapeutics (CTMX) | 0.3 | $1.6M | +90% | 438k | 3.75 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.3 | $1.6M | -22% | 47k | 33.39 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.3 | $1.5M | NEW | 226k | 6.61 |
|
| Design Therapeutics (DSGN) | 0.3 | $1.5M | NEW | 103k | 14.47 |
|
| Fate Therapeutics (FATE) | 0.3 | $1.4M | -4% | 525k | 2.70 |
|
| Mediwound Shs New (MDWD) | 0.3 | $1.4M | 94k | 14.70 |
|
|
| Kura Oncology (KURA) | 0.3 | $1.3M | -48% | 121k | 10.97 |
|
| Silverback Therapeutics (SPRY) | 0.3 | $1.3M | +17% | 164k | 8.01 |
|
| Mineralys Therapeutics (MLYS) | 0.2 | $1.2M | +15% | 45k | 26.98 |
|
| Immatics Nv SHS (IMTX) | 0.2 | $1.2M | -48% | 117k | 10.13 |
|
| Tela Bio (TELA) | 0.2 | $1.1M | 1.4M | 0.75 |
|
|
| Polypid (PYPD) | 0.2 | $1.1M | 208k | 5.08 |
|
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.2 | $1.0M | NEW | 108k | 9.38 |
|
| Inspire Med Sys (INSP) | 0.2 | $812k | 18k | 44.61 |
|
|
| Adicet Bio Com New (ACET) | 0.2 | $811k | 94k | 8.64 |
|
|
| Seaport Therapeutics Common Stock | 0.1 | $704k | NEW | 32k | 21.72 |
|
| Mbx Biosciences (MBX) | 0.1 | $652k | -93% | 12k | 55.20 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.1 | $651k | 7.0k | 93.05 |
|
|
| Artiva Biotherapeutics (ARTV) | 0.1 | $651k | NEW | 67k | 9.70 |
|
| Pliant Therapeutics (PLRX) | 0.1 | $555k | 487k | 1.14 |
|
|
| Scynexis | 0.1 | $553k | NEW | 136k | 4.07 |
|
| Editas Medicine (EDIT) | 0.1 | $552k | NEW | 171k | 3.24 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.1 | $547k | 127k | 4.32 |
|
|
| Foghorn Therapeutics (FHTX) | 0.1 | $546k | 112k | 4.88 |
|
|
| Accuray Incorporated (ARAY) | 0.1 | $433k | 1.7M | 0.26 |
|
|
| Q32 Bio (QTTB) | 0.1 | $419k | NEW | 33k | 12.74 |
|
| Nuvectis Pharma (NVCT) | 0.1 | $368k | NEW | 20k | 18.39 |
|
| Compugen Ord (CGEN) | 0.1 | $360k | -34% | 168k | 2.14 |
|
| Ibio Com New (IBIO) | 0.1 | $298k | -12% | 170k | 1.75 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $287k | 179k | 1.60 |
|
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 0.1 | $273k | 65k | 4.24 |
|
|
| Tenaya Therapeutics (TNYA) | 0.0 | $222k | NEW | 300k | 0.74 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.0 | $145k | -84% | 24k | 6.12 |
|
| Engene Therapeutics (ENGN) | 0.0 | $129k | NEW | 75k | 1.73 |
|
| Kardigan Ord | 0.0 | $119k | NEW | 5.0k | 23.85 |
|
| Adc Therapeutics Sa SHS (ADCT) | 0.0 | $83k | +6% | 77k | 1.07 |
|
Past Filings by DAFNA Capital Management
SEC 13F filings are viewable for DAFNA Capital Management going back to 2010
- DAFNA Capital Management 2026 Q2 filed Aug. 14, 2026
- DAFNA Capital Management 2026 Q1 filed May 15, 2026
- DAFNA Capital Management 2025 Q4 filed Feb. 17, 2026
- DAFNA Capital Management 2025 Q3 filed Nov. 14, 2025
- DAFNA Capital Management 2025 Q2 filed Aug. 14, 2025
- DAFNA Capital Management 2025 Q1 filed May 15, 2025
- DAFNA Capital Management 2024 Q4 filed Feb. 14, 2025
- DAFNA Capital Management 2024 Q3 filed Nov. 14, 2024
- DAFNA Capital Management 2024 Q2 filed Aug. 14, 2024
- DAFNA Capital Management 2024 Q1 filed May 15, 2024
- DAFNA Capital Management 2023 Q4 filed Feb. 14, 2024
- DAFNA Capital Management 2023 Q3 filed Nov. 14, 2023
- DAFNA Capital Management 2023 Q2 filed Aug. 14, 2023
- DAFNA Capital Management 2023 Q1 filed May 15, 2023
- DAFNA Capital Management 2022 Q4 filed Feb. 14, 2023
- DAFNA Capital Management 2022 Q3 filed Nov. 14, 2022